Precigen Inc PGEN presented positive interim data at the ASH Annual Meeting and Exposition from the ongoing Phase 1/1b study of PRGN-3006 UltraCAR-T in relapsed or refractory (r/r) acute myeloid leukemia and higher-risk myelodysplastic syndromes.
- PRGN-3006 UltraCAR-T is a multigenic autologous CAR-T simultaneously expressing a CAR targeting CD33.
- PRGN-3006 was well-tolerated with no dose-limiting toxicities (DLTs) and no neurotoxicity at any dose level.
- Overall, there was a low incidence of adverse events following PRGN-3006 infusion, and the most common adverse events were decreased lymphocyte count, anemia, and cytokine release syndrome (CRS).
- In the non-lymphodepletion cohort, UltraCAR-T cells could be detected in blood for more than seven months post-infusion.
- Peak expansion was observed between days 7 and 21 in the peripheral blood.
- Three out of 9 (33%) patients had Stable Disease (SD), with one patient experiencing durable SD for more than seven months with a concomitant reduction in peripheral blast levels.
- In the lymphodepletion cohort, UltraCAR-T cells could be detected in the blood more than three months post-infusion. Peak expansion was observed between days 14 and 21 in the peripheral blood.
- Higher peak expansion (over 10 fold) was observed in the lymphodepletion cohort at the same dose level.
- An ORR of 50% was reported in the lymphodepletion cohort in patients treated at the two lowest dose levels.
- One responder subsequently received allo-HSCT with ongoing survival of over one year.
- Price Action: PGEN shares traded lower by 2.43% at $3.61 during premarket trading on Tuesday.
- Check out our coverage of the American Society of Hematology (ASH) Annual Meeting 2021 here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapGeneralacute myeloid leukemiaASH21Briefsmyelodysplastic syndromePhase 1 Trial
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in